BRISTOL-MYERS SQUIBB COMPANY Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability of $14.39 billion for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:QuarterlyFinancialInformationQuarterlyChargesAndCreditsAmountAffectingComparability · last filed 2021-02-10
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for the quarter ending 2020-12-31 was $14.39B, a 398.68% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for the quarter ending 2020-09-30 was $2.26B, a 168.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for the quarter ending 2020-06-30 was $2.73B, a 346.08% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for the quarter ending 2020-03-31 was $5.02B, a 3565.69% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for fiscal 2020 was $24.40B, a 445.25% increase from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for fiscal 2019 was $4.47B, a 133.07% increase from fiscal 2018.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for fiscal 2018 was $1.92B, a 60.27% increase from fiscal 2017.
- BRISTOL-MYERS SQUIBB COMPANY quarterly financial information, quarterly charges and credits, amount affecting comparability for fiscal 2017 was $1.20B, a 395.04% increase from fiscal 2016.
| Period end | Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability 3 month | Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability 6 month | Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability 9 month | Quarterly Financial Information, Quarterly Charges and Credits, Amount Affecting Comparability 12 month |
|---|---|---|---|---|
| 2020-12-31 | $14.39B 10-K · filed 2021-02-10 | $16.65B derived: sum of 2 quarters · filed 2021-02-10 | $19.38B derived: sum of 3 quarters · filed 2021-02-10 | $24.40B 10-K · filed 2021-02-10 |
| 2020-09-30 | $2.26B 10-K · filed 2021-02-10 | $4.99B derived: sum of 2 quarters · filed 2021-02-10 | $10.01B derived: sum of 3 quarters · filed 2021-02-10 | $12.89B derived: sum of 4 quarters · filed 2021-02-10 |
| 2020-06-30 | $2.73B 10-K · filed 2021-02-10 | $7.75B derived: sum of 2 quarters · filed 2021-02-10 | $10.64B derived: sum of 3 quarters · filed 2021-02-10 | $11.48B derived: sum of 4 quarters · filed 2021-02-10 |
| 2020-03-31 | $5.02B 10-K · filed 2021-02-10 | $7.91B derived: sum of 2 quarters · filed 2021-02-10 | $8.75B derived: sum of 3 quarters · filed 2021-02-10 | $9.36B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-12-31 | $2.89B 10-K · filed 2021-02-10 | $3.73B derived: sum of 2 quarters · filed 2021-02-10 | $4.34B derived: sum of 3 quarters · filed 2021-02-10 | $4.47B 10-K · filed 2021-02-10 |
| 2019-09-30 | $840.00M 10-K · filed 2021-02-10 | $1.45B derived: sum of 2 quarters · filed 2021-02-10 | $1.59B derived: sum of 3 quarters · filed 2021-02-10 | $2.02B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $612.00M 10-K · filed 2021-02-10 | $749.00M derived: sum of 2 quarters · filed 2021-02-10 | $1.18B derived: sum of 3 quarters · filed 2021-02-10 | $1.08B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $137.00M 10-K · filed 2021-02-10 | $570.00M derived: sum of 2 quarters · filed 2021-02-10 | $468.00M derived: sum of 3 quarters · filed 2021-02-10 | $1.96B derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $433.00M 10-K · filed 2020-02-24 | $331.00M derived: sum of 2 quarters · filed 2020-02-24 | $1.82B derived: sum of 3 quarters · filed 2020-02-24 | $1.92B 10-K · filed 2020-02-24 |
| 2018-09-30 | -$102.00M 10-K · filed 2020-02-24 | $1.39B derived: sum of 2 quarters · filed 2020-02-24 | $1.49B derived: sum of 3 quarters · filed 2020-02-24 | $2.17B derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $1.49B 10-K · filed 2020-02-24 | $1.59B derived: sum of 2 quarters · filed 2020-02-24 | $2.27B derived: sum of 3 quarters · filed 2020-02-24 | $2.69B derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $101.00M 10-K · filed 2020-02-24 | $779.00M derived: sum of 2 quarters · filed 2020-02-24 | $1.20B derived: sum of 3 quarters · filed 2020-02-24 | $1.49B derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $678.00M 10-K · filed 2019-02-25 | $1.10B derived: sum of 2 quarters · filed 2019-02-25 | $1.39B derived: sum of 3 quarters · filed 2019-02-25 | $1.20B 10-K · filed 2019-02-25 |
| 2017-09-30 | $425.00M 10-K · filed 2019-02-25 | $707.00M derived: sum of 2 quarters · filed 2019-02-25 | $520.00M derived: sum of 3 quarters · filed 2019-02-25 | $795.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $282.00M 10-K · filed 2019-02-25 | $95.00M derived: sum of 2 quarters · filed 2019-02-25 | $370.00M derived: sum of 3 quarters · filed 2019-02-25 | $458.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | -$187.00M 10-K · filed 2019-02-25 | $88.00M derived: sum of 2 quarters · filed 2019-02-25 | $176.00M derived: sum of 3 quarters · filed 2019-02-25 | $98.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $275.00M 10-K · filed 2018-02-13 | $363.00M derived: sum of 2 quarters · filed 2018-02-13 | $285.00M derived: sum of 3 quarters · filed 2018-02-13 | $242.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | $88.00M 10-K · filed 2018-02-13 | $10.00M derived: sum of 2 quarters · filed 2018-02-13 | -$33.00M derived: sum of 3 quarters · filed 2018-02-13 | $1.15B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$78.00M 10-K · filed 2018-02-13 | -$121.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.06B derived: sum of 3 quarters · filed 2018-02-13 | $961.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | -$43.00M 10-K · filed 2018-02-13 | $1.14B derived: sum of 2 quarters · filed 2018-02-13 | $1.04B derived: sum of 3 quarters · filed 2018-02-13 | $2.17B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $1.18B 10-K · filed 2017-02-21 | $1.08B derived: sum of 2 quarters · filed 2017-02-21 | $2.22B derived: sum of 3 quarters · filed 2017-02-21 | $2.29B 10-K · filed 2017-02-21 |
| 2015-09-30 | -$101.00M 10-K · filed 2017-02-21 | $1.03B derived: sum of 2 quarters · filed 2017-02-21 | $1.11B derived: sum of 3 quarters · filed 2017-02-21 | $2.04B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $1.14B 10-K · filed 2017-02-21 | $1.21B derived: sum of 2 quarters · filed 2017-02-21 | $2.14B derived: sum of 3 quarters · filed 2017-02-21 | $2.14B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $75.00M 10-K · filed 2017-02-21 | $1.01B derived: sum of 2 quarters · filed 2017-02-21 | $1.00B derived: sum of 3 quarters · filed 2017-02-21 | $1.57B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $932.00M 10-K · filed 2016-02-12 | $928.00M derived: sum of 2 quarters · filed 2016-02-12 | $1.50B derived: sum of 3 quarters · filed 2016-02-12 | $1.50B 10-K · filed 2016-02-12 |
| 2014-09-30 | -$4.00M 10-K · filed 2016-02-12 | $563.00M derived: sum of 2 quarters · filed 2016-02-12 | $571.00M derived: sum of 3 quarters · filed 2016-02-12 | $738.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $567.00M 10-K · filed 2016-02-12 | $575.00M derived: sum of 2 quarters · filed 2016-02-12 | $742.00M derived: sum of 3 quarters · filed 2016-02-12 | $858.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $8.00M 10-K · filed 2016-02-12 | $175.00M derived: sum of 2 quarters · filed 2016-02-12 | $291.00M derived: sum of 3 quarters · filed 2016-02-12 | $601.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $167.00M 10-K · filed 2015-02-13 | $283.00M derived: sum of 2 quarters · filed 2015-02-13 | $593.00M derived: sum of 3 quarters · filed 2015-02-13 | $698.00M 10-K · filed 2015-02-13 |
| 2013-09-30 | $116.00M 10-K · filed 2015-02-13 | $426.00M derived: sum of 2 quarters · filed 2015-02-13 | $531.00M derived: sum of 3 quarters · filed 2015-02-13 | $931.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $310.00M 10-K · filed 2015-02-13 | $415.00M derived: sum of 2 quarters · filed 2015-02-13 | $815.00M derived: sum of 3 quarters · filed 2015-02-13 | $2.93B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $105.00M 10-K · filed 2015-02-13 | $505.00M derived: sum of 2 quarters · filed 2015-02-13 | $2.62B derived: sum of 3 quarters · filed 2015-02-13 | $2.86B derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $400.00M 10-K · filed 2014-02-14 | $2.52B derived: sum of 2 quarters · filed 2014-02-14 | $2.76B derived: sum of 3 quarters · filed 2014-02-14 | $2.74B 10-K · filed 2014-02-14 |
| 2012-09-30 | $2.12B 10-K · filed 2014-02-14 | $2.36B derived: sum of 2 quarters · filed 2014-02-14 | $2.34B derived: sum of 3 quarters · filed 2014-02-14 | $2.46B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $240.00M 10-K · filed 2014-02-14 | $225.00M derived: sum of 2 quarters · filed 2014-02-14 | $342.00M derived: sum of 3 quarters · filed 2014-02-14 | $454.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | -$15.00M 10-K · filed 2014-02-14 | $102.00M derived: sum of 2 quarters · filed 2014-02-14 | $214.00M derived: sum of 3 quarters · filed 2014-02-14 | $332.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $117.00M 10-K · filed 2013-02-15 | $229.00M derived: sum of 2 quarters · filed 2013-02-15 | $347.00M derived: sum of 3 quarters · filed 2013-02-15 | $445.00M 10-K · filed 2013-02-15 |
| 2011-09-30 | $112.00M 10-K · filed 2013-02-15 | $230.00M derived: sum of 2 quarters · filed 2013-02-15 | $328.00M derived: sum of 3 quarters · filed 2013-02-15 | |
| 2011-06-30 | $118.00M 10-K · filed 2013-02-15 | $216.00M derived: sum of 2 quarters · filed 2013-02-15 | ||
| 2011-03-31 | $98.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |